Arcus Biosciences PE Ratio 2017-2023 | RCUS
Current and historical p/e ratio for Arcus Biosciences (RCUS) from 2017 to 2023. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Arcus Biosciences PE ratio as of May 31, 2023 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Arcus Biosciences PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2023-05-31 |
20.54 |
|
0.00 |
| 2023-03-31 |
18.24 |
$-3.85 |
0.00 |
| 2022-12-31 |
20.68 |
$-3.72 |
0.00 |
| 2022-09-30 |
26.16 |
$0.92 |
28.43 |
| 2022-06-30 |
25.34 |
$0.71 |
35.69 |
| 2022-03-31 |
31.56 |
$0.55 |
57.38 |
| 2021-12-31 |
40.47 |
$0.43 |
94.12 |
| 2021-09-30 |
34.87 |
$-4.10 |
0.00 |
| 2021-06-30 |
27.46 |
$-2.96 |
0.00 |
| 2021-03-31 |
28.08 |
$-2.80 |
0.00 |
| 2020-12-31 |
25.96 |
$-2.35 |
0.00 |
| 2020-09-30 |
17.14 |
$-1.91 |
0.00 |
| 2020-06-30 |
24.74 |
$-2.45 |
0.00 |
| 2020-03-31 |
13.88 |
$-2.16 |
0.00 |
| 2019-12-31 |
10.10 |
$-1.94 |
0.00 |
| 2019-09-30 |
9.10 |
$-1.84 |
0.00 |
| 2019-06-30 |
7.95 |
$-1.58 |
0.00 |
| 2019-03-31 |
12.49 |
$-1.26 |
0.00 |
| 2018-12-31 |
10.77 |
$-2.22 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.481B |
$0.112B |
|
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
|
